Arnold, Douglas MD

Professor

McGill University, Montreal Neurological Institute
3801 University Street, Montreal, QC H3A 2B4
514-398-8185
514-398-2957

Research Profile

Advanced MRI acquisition and analysis methods for evaluation of multiple sclerosis (MS) and other neurological disorders.

Expertise

MRI, MRS, Multiple Sclerosis, Neurological disorders

Recent Publications

  • Grover SA, Aubert-Broche B, Fetco D, Collins DL, Arnold DL, Finlayson M, Banwell BL, Motl RW, Yeh EA. Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001939. In Press.
  • Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler. 2015 Jul 21. pii: 1352458515595876. In Press.
  • Rocca MA, Sonkin M, Copetti M, Pagani E, Arnold DL, Narayanan S, Sled JG, Banwell B, Filippi M. Diffusion tensor magnetic resonance imaging in very early onset pediatric multiple sclerosis. Mult Scler. 2015 Jul 21. pii: 1352458515596600. In Press.
  • Karimaghaloo Z, Arnold DL, Arbel T. Adaptive multi-level conditional random fields for detection and segmentation of small enhanced pathology in medical images. Med Image Anal. 2015 Jul 11. pii: S1361-8415(15)00091-2. doi: 10.1016/j.media.2015.06.004. In Press.
  • Schipper HM, Arnold D, GrandʼMaison F, Melmed C, Moore F, Levental M, Su H, Constantin M, Stril JL, Godin J. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis. Clin Neuropharmacol. 2015 Jul-Aug;38(4):127-31. doi: 10.1097/WNF.0000000000000090.
  • Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986..
  • Nakamura K, Brown RA, Narayanan S, Collins DL, Arnold DL; Alzheimer's Disease Neuroimaging Initiative. Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. Neuroimage. 2015 Jun 3;118:126-132. doi: 10.1016/j.neuroimage.2015.05.077. In Press.
  • Karimaghaloo Z, Rivaz H, Arnold DL, Collins DL, Arbel T. Temporal Hierarchical Adaptive Texture CRF for Automatic Detection of Gadolinium-Enhancing Multiple Sclerosis Lesions in Brain MRI. IEEE Trans Med Imaging. 2015 Jun;34(6):1227-41. doi: 10.1109/TMI.2014.2382561.
  • Ghassemi R, Brown R, Banwell B, Narayanan S, Arnold DL; Canadian Pediatric Demyelinating Disease Study Group. Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis. Mult Scler. 2015 May;21(6):718-25. doi: 10.1177/1352458514551594..
  • Harmouche R, Subbanna NK, Collins DL, Arnold DL, Arbel T. Probabilistic multiple sclerosis lesion classification based on modeling regional intensity variability and local neighborhood information. IEEE Trans Biomed Eng. 2015 May;62(5):1281-92. doi: 10.1109/TBME.2014.2385635.
  • De Stefano N, Arnold DL. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult Scler. 2015 May;21(6):675-6. doi: 10.1177/1352458514564494.
  • Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ; DEFINE and CONFIRM study investigators. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015 Apr;22(4):664-71. doi: 10.1111/ene.12624.
  • Ghassemi R, Brown R, Narayanan S, Banwell B, Nakamura K, Arnold DL. Normalization of white matter intensity on T1-weighted images of patients with acquired central nervous system demyelination. J Neuroimaging. 2015 Mar-Apr;25(2):184-90. doi: 10.1111/jon.12129.
  • Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.
  • Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015 Feb;2(2):103-18. doi: 10.1002/acn3.148.
  • Subbanna N, Precup D, Arnold D, Arbel T. IMaGe: Iterative Multilevel Probabilistic Graphical Model for Detection and Segmentation of Multiple Sclerosis Lesions in Brain MRI. Inf Process Med Imaging. 2015;24:514-26.
  • Guizard N, Coupé P, Fonov VS, Manjón JV, Arnold DL, Collins DL. Rotation-invariant multi-contrast non-local means for MS lesion segmentation. Neuroimage Clin. 2015 May 13;8:376-89. doi: 10.1016/j.nicl.2015.05.001. eCollection 2015.
  • Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol. 2014 Dec 31;14:240. doi: 10.1186/s12883-014-0240-x.
  • Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, Fetco D, Hussain M, O'Mahony J, Magalhaes S, McGowan M, Johnson T, Rajasekharan S, Narayanan S, Arnold DL, Weiner HL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology. 2014 Dec 9;83(24):2219-26. doi: 10.1212/WNL.0000000000001066.
  • Aubert-Broche B, Fonov V, Narayanan S, Arnold DL, Araujo D, Fetco D, Till C, Sled JG, Banwell B, Collins DL; Canadian Pediatric Demyelinating Disease Network. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology. 2014 Dec 2;83(23):2140-6. doi: 10.1212/WNL.0000000000001045.
  • Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol. 2014 Dec;261(12):2429-37. doi: 10.1007/s00415-014-7504-7.
  • Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol. 2014 Sep;261(9):1794-802. doi: 10.1007/s00415-014-7412-x.
  • Derakhshan M, Caramanos Z, Narayanan S, Arnold DL, Louis Collins D. Surface-based analysis reveals regions of reduced cortical magnetization transfer ratio in patients with multiple sclerosis: a proposed method for imaging subpial demyelination. Hum Brain Mapp. 2014 Jul;35(7):3402-13. doi: 10.1002/hbm.22410.
  • Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7.
  • Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4.
  • Leppert IR, Narayanan S, Araújo D, Giacomini PS, Lapierre Y, Arnold DL, Pike GB. Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't. J Neurol. 2014 Apr;261(4):809-16. doi: 10.1007/s00415-014-7284-0.
  • Trojan DA, Narayanan S, Francis SJ, Caramanos Z, Robinson A, Cardoso M, Arnold DL. Brain volume and fatigue in patients with postpoliomyelitis syndrome. PM R. 2014 Mar;6(3):215-20. doi: 10.1016/j.pmrj.2013.09.009.
  • Sormani MP, Arnold DL, De Stefano N. Reply: To PMID 24006277. Ann Neurol. 2014 Mar;75(3):463-4. doi: 10.1002/ana.24111.
  • Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014 Feb;20(2):243-52. doi: 10.1177/1352458513507817.
  • Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A; Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014 Jan 30;370(5):486-8. doi: 10.1056/NEJMc1304828.
  • Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43-9. doi: 10.1002/ana.24018.
  • Nakamura K, Guizard N, Fonov VS, Narayanan S, Collins DL, Arnold DL. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin. 2013 Oct 29;4:10-7. doi: 10.1016/j.nicl.2013.10.015. eCollection 2014.
  • Ghassemi R, Narayanan S, Banwell B, Sled JG, Shroff M, Arnold DL; Canadian Pediatric Demyelinating Disease Network. Quantitative determination of regional lesion volume and distribution in children and adults with relapsing-remitting multiple sclerosis. PLoS One. 2014 Feb 26;9(2):e85741. doi: 10.1371/journal.pone.0085741. eCollection 2014.
  • Nakamura K, Brown RA, Araujo D, Narayanan S, Arnold DL. Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: implications for monitoring atrophy in clinical studies. Neuroimage Clin. 2014 Aug 23;6:166-70. doi: 10.1016/j.nicl.2014.08.014. eCollection 2014.
  • Brown RA, Narayanan S, Banwell B, Arnold DL; Canadian Pediatric Demyelinating Disease Network. Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients. Neuroimage Clin. 2014 Sep 10;6:237-42. doi: 10.1016/j.nicl.2014.09.003. eCollection 2014.
  • Brown RA, Narayanan S, Arnold DL. Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis. Neuroimage Clin. 2014 Aug 15;6:20-5. doi: 10.1016/j.nicl.2014.06.009. eCollection 2014.